Literature DB >> 18295907

Advances in FIV vaccine technology.

Elizabeth W Uhl1, Marcus Martin, James K Coleman, Janet K Yamamoto.   

Abstract

Advances in vaccine technology are occurring in the molecular techniques used to develop vaccines and in the assessment of vaccine efficacy, allowing more complete characterization of vaccine-induced immunity correlating to protection. FIV vaccine development has closely mirrored and occasionally surpassed the development of HIV-1 vaccine, leading to first licensed technology. This review will discuss technological advances in vaccine designs, challenge infection assessment, and characterization of vaccine immunity in the context of the protection detected with prototype and commercial dual-subtype FIV vaccines and in relation to HIV-1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295907      PMCID: PMC3581037          DOI: 10.1016/j.vetimm.2008.01.030

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  73 in total

1.  Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.

Authors:  Margaret J Hosie; Dieter Klein; James M Binley; Thomas H Dunsford; Oswald Jarrett; James C Neil; Elzbieta Knapp; Simone Giannecchini; Donatella Matteucci; Mauro Bendinelli; James A Hoxie; Brian J Willett
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  HIV vaccine development by computer assisted design: the GAIA vaccine.

Authors:  Anne S De Groot; Luisa Marcon; Elizabeth A Bishop; Daniel Rivera; Michele Kutzler; David B Weiner; William Martin
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

Review 3.  [Evolution of lentiviruses and receptor specificity].

Authors:  Takayuki Miyazawa
Journal:  Uirusu       Date:  2005-06

Review 4.  Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences.

Authors:  Jason T Blackard; Daniel E Cohen; Kenneth H Mayer
Journal:  Clin Infect Dis       Date:  2002-03-15       Impact factor: 9.079

5.  Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.

Authors:  G J Gorse; G B Patel; M D Mandava; R B Belshe
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

Review 6.  Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.

Authors:  Ruiyu Pu; James Coleman; James Coisman; Eiji Sato; Taishi Tanabe; Maki Arai; Janet K Yamamoto
Journal:  J Feline Med Surg       Date:  2005-02       Impact factor: 2.015

7.  Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.

Authors:  R Pu; J Coleman; M Omori; M Arai; T Hohdatsu; C Huang; T Tanabe; J K Yamamoto
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

Review 8.  Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine.

Authors:  Janet K Yamamoto; Ruiyu Pu; Eiji Sato; Tsutomu Hohdatsu
Journal:  AIDS       Date:  2007-03-12       Impact factor: 4.177

9.  Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.

Authors:  Daniel E Kaufmann; Paul M Bailey; John Sidney; Bradford Wagner; Philip J Norris; Mary N Johnston; Lisa A Cosimi; Marylyn M Addo; Mathias Lichterfeld; Marcus Altfeld; Nicole Frahm; Christian Brander; Alessandro Sette; Bruce D Walker; Eric S Rosenberg
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 10.  HIV's evasion of host's NK cell response and novel ways of its countering and boosting anti-HIV immunity.

Authors:  Ali Ahmad; Rasheed Ahmad
Journal:  Curr HIV Res       Date:  2003-07       Impact factor: 1.581

View more
  19 in total

1.  Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.

Authors:  James K Coleman; Ruiyu Pu; Marcus M Martin; Ezra N Noon-Song; Raphael Zwijnenberg; Janet K Yamamoto
Journal:  Vaccine       Date:  2013-06-22       Impact factor: 3.641

2.  Role of the feline immunodeficiency virus L-domain in the presence or absence of Gag processing: involvement of ubiquitin and Nedd4-2s ligase in viral egress.

Authors:  Arianna Calistri; Claudia Del Vecchio; Cristiano Salata; Michele Celestino; Marta Celegato; Heinrich Göttlinger; Giorgio Palù; Cristina Parolin
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

3.  Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.

Authors:  Shannon R Roff; Missa P Sanou; Mobeen H Rathore; Jay A Levy; Janet K Yamamoto
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Feline immunodeficiency virus model for designing HIV/AIDS vaccines.

Authors:  Janet K Yamamoto; Missa P Sanou; Jeffrey R Abbott; James K Coleman
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

5.  Formation of RNA Granule-Derived Capsid Assembly Intermediates Appears To Be Conserved between Human Immunodeficiency Virus Type 1 and the Nonprimate Lentivirus Feline Immunodeficiency Virus.

Authors:  Jonathan C Reed; Nick Westergreen; Brook C Barajas; Dylan T B Ressler; Daryl J Phuong; John V Swain; Vishwanath R Lingappa; Jaisri R Lingappa
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

Review 6.  Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine.

Authors:  J R Abbott; M P Sanou; J K Coleman; J K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2011-06-12       Impact factor: 2.046

7.  Mapping of Receptor Binding Interactions with the FIV surface Glycoprotein (SU); Implications Regarding Immune surveillance and cellular Targets of Infection.

Authors:  Qiong-Ying Hu; Elizabeth Fink; John H Elder
Journal:  Retrovirology (Auckl)       Date:  2012-07-11

8.  Fine definition of the CXCR4-binding region on the V3 loop of feline immunodeficiency virus surface glycoprotein.

Authors:  Qiong-Ying Hu; Elizabeth Fink; Yang Hong; Cathy Wang; Chris K Grant; John H Elder
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

9.  An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection.

Authors:  Alek M Aranyos; Shannon R Roff; Ruiyu Pu; Jennifer L Owen; James K Coleman; Janet K Yamamoto
Journal:  Vaccine       Date:  2016-01-21       Impact factor: 3.641

Review 10.  The utilization of humanized mouse models for the study of human retroviral infections.

Authors:  Rachel Van Duyne; Caitlin Pedati; Irene Guendel; Lawrence Carpio; Kylene Kehn-Hall; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-08-12       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.